Androgenic Alopecia: Recent Understanding Of The Androgenetic Receptor-Mediated Molecular Mechanisms And Current Pharmacotherapy

This study found that finasteride-loaded nanostructured lipid carriers developed for topical application showed satisfactory size, stability, and prolonged drug release, suggesting potential for enhanced delivery in androgenic alopecia treatment.

This study found that topical minoxidil 5% gel and spironolactone 1% gel were both effective treatments for androgenetic alopecia, with a combination of both providing the best clinical response and achieving 100% effectiveness among participants.

This review discusses current topical treatments, natural products, and complementary therapies for androgenetic alopecia, but it reports no new clinical results.

This article discusses the potential for topical caffeine as a natural alternative for treating androgenetic alopecia due to its ability to penetrate skin, but it reports no new clinical findings.

In this study, researchers found that topical ketoconazole showed delayed hair growth compared to minoxidil in female pattern hair loss but had fewer side effects, though patient satisfaction was similar for both treatments.

This review discusses the potential benefits of phytochemicals for hair care and emphasizes the need for more robust preclinical and clinical studies, without reporting new clinical results.

This study reported that oleic acid-based nanovesicles improve follicular delivery and reduce side effects of minoxidil compared to traditional MXD lotions.

This study found that melatonin-loaded vitamin C-based nanovesicles improved hair thickness, density, and reduced hair loss in patients with androgenic alopecia more effectively than melatonin solution.

In this study, researchers reviewed literature on topical delivery of finasteride for androgenetic alopecia, finding that liposomal gels with specific additives showed the highest skin permeation rates, suggesting potential for reducing systemic side effects compared to oral formulations.

This review discusses the psychological impact of alopecia on women and reports no new clinical findings, highlighting the effect on self-esteem and quality of life.

This study found that co-delivery of minoxidil and caffeine in transfersomes with an optimized polysorbate formulation enhanced hair length and weight in vivo.

This review discusses the molecular mechanisms of androgens and androgen receptors in skin disorders, particularly androgenetic alopecia, and reports no new clinical results; it highlights potential areas for future treatment development.

This article discusses the role of androgens in metabolic and reproductive health and reports no new experimental results; the focus is on androgen receptor activation by testosterone and 5α-dihydrotestosterone.

This review discusses current and emerging therapeutic strategies for androgenetic alopecia, noting limited evidence but suggesting areas such as prostaglandin analogs, PRP, and progenitor cell therapies as promising future directions.

This review examines recent advances in understanding the pathophysiology and molecular mechanisms of androgenetic alopecia, highlighting two major genetic risk loci, but does not report new clinical findings.

In this study, researchers found that the prevalence of androgenetic alopecia was higher in their sample compared to other studies in Asian and Caucasian populations, and it was linked with age-related severity.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

In this study, male participants with early androgenetic alopecia experienced a significant increase in hair growth rate after applying topical lipoid cepharanthine lotion for six months.

This review discusses the emerging pathophysiological factors and potential new therapies for androgenetic alopecia beyond traditional treatments, but reports no new results.

Tiny particles carrying roxithromycin can effectively target and deliver the drug to hair follicles without irritation.

This study reports that severe androgenic alopecia prevalence in young Caucasian men increases with age, varies by region, and that body mass index may be a risk factor.

This study found that the MorrF topical solution combination showed significantly better hair growth improvements than Minoxidil alone in male patients with Androgenetic Alopecia.

This study suggests that spironolactone-loaded nanostructured lipid carriers could enhance follicular delivery and offer a more localized treatment for androgenic alopecia, potentially reducing systemic side effects.

This review discusses the mechanisms and treatment strategies for age-related hair changes, such as androgenetic alopecia and hair graying, and reports no new clinical results.

Applying valproic acid on the scalp increased hair growth in men with hair loss.

This study found that caffeine enhanced hair growth and keratinocyte proliferation in human hair follicles, with female follicles showing greater sensitivity than male ones.

This review outlines the mechanisms, clinical features, and management strategies for alopecia areata and presents no new experimental findings.

This review summarizes drug delivery strategies to hair follicles, highlighting physicochemical factors affecting penetration and the use of stimuli-responsive particulate carriers, but reports no new clinical findings.

This review discusses the presence of the StAR protein in 17 non-classical steroidogenic tissues, suggesting that advanced detection methods are needed for a complete understanding of its functions in these tissues.

This review discusses recent advances in hair follicle biology, regeneration, and tissue engineering, highlighting emerging therapeutic opportunities, and reports no new experimental results.

This article reviews recent advancements in understanding and treating androgenetic alopecia, focusing on new genetic insights, stem cell roles, and diagnostic tools, without reporting new clinical results.

This article reviews the pathophysiology, diagnosis, and treatment of female pattern hair loss, highlighting the importance of early medical intervention to arrest hair loss progression, but reports no new clinical results.

This review discusses the development of an algorithmic guideline for treating androgenetic alopecia in Asian patients, using the BASP classification to address limitations of previous guidelines, and reports no clinical results.

This study found that using a protease-triggered release system enabled effective delivery of a model drug deep within porcine hair follicles, suggesting a new approach for treating skin conditions.

This review discusses current treatment options for hirsutism, emphasizing the importance of combining therapies for better outcomes, but reports no new clinical findings.

This article reviews existing treatments for male-pattern hair loss, noting that while they can slow progression, they generally achieve only partial hair regrowth.

This study observed that a topical liposome formulation of a 5‐α‐reductase inhibitor effectively reduced the size of treated sebaceous glands and induced apoptosis in a hamster model, suggesting potential benefits for acne treatment.

This review covers follicle-targeting drug delivery systems, exploring their potential for improving localized and systemic therapies, and highlights the need for further research into follicle penetration mechanisms.

This review discusses the role of androgen metabolism and perifollicular inflammation in the progression of androgenetic alopecia and reports no new clinical results.

This review summarizes recent advancements in follicular targeting for drug delivery via hair follicles and calls for pilot studies in humans to explore potential clinical applications.

This chapter discusses the increasing prevalence of overactive bladder in aging men, examining potential causes and treatment options, without reporting new clinical results.

In this study, topical 5% roxithromycin was effective in restoring hair growth in about half of individuals with androgenetic alopecia without causing adverse effects.

This article discusses treatment options for androgenetic alopecia, noting that medical interventions like finasteride and minoxidil can halt and partially reverse hair loss in mild to moderate cases, especially when combined with surgery.

In this study, caffeine applied in a shampoo penetrated hair follicles faster and more effectively than through the skin surface within the first 20 minutes.

This review discusses the multifaceted roles of hair follicles in skin health, including potential contributions to skin neoplasias, and reports no new results.

This article reviews the stages and regulation of the hair cycle, highlighting molecular regulators involved, but it does not present new research findings.

This study found that the prevalence of androgenetic alopecia increases with age among both men and women in Maryborough, Australia, with 57% of women and 73.5% of men aged 80 and over affected.

This study found that 2% ketoconazole solution stimulated hair growth significantly in a mouse model, suggesting potential benefits for male pattern hair loss.

This review discusses the development, function, and complex roles of sebaceous glands in acne and suggests future acne treatments should target inflammation and lipid production; it reports no new clinical results.

This paper suggests that ketoconazole 2% shampoo may enhance finasteride's effectiveness in treating androgenetic alopecia by more completely inhibiting the dihydrotestosterone pathway.

This review discusses the genetic factors contributing to androgenetic alopecia and highlights the potential for developing more effective therapies based on recent discoveries, but reports no new clinical results.

This paper discusses key mechanisms of androgen metabolism in androgenetic alopecia and reports the effectiveness of treatments like oral finasteride and topical minoxidil, highlighting the limited success rate due to factors like follicular inflammation.

In vitro, this study suggests that CRH may act as an autocrine hormone in human sebocytes, influencing lipid synthesis and potentially impacting skin disorders related to alterations in sebaceous lipid formation.

In this study, finasteride, 1 mg daily, significantly increased hair weight more than hair count in men with androgenetic alopecia, indicating additional factors like hair growth rate and thickness may contribute to its effectiveness.

This study found that finasteride increases anagen hair growth in men with androgenetic alopecia.

In a study using human scalp skin grafts on SCID mice, topical flutamide and finasteride significantly improved hair growth in male-pattern baldness compared to placebo, with flutamide showing superior results to finasteride.

This article discusses the biologic and psychosocial significance of hair, the current limitations in hair growth drugs, and anticipates future therapies based on advancing hair follicle research.

This study reported that finasteride 1 mg/day significantly increased hair growth and slowed hair loss in men with frontal scalp hair thinning over one year, and these benefits continued or improved in the second year.

Apoptosis in hair follicles varies by growth phase, with TGF-β possibly starting the catagen phase.

In male pattern hair loss, this study found that finasteride 1 mg daily significantly slowed hair loss and increased hair growth over two years compared to placebo.

This study reported that a 0.005% finasteride solution may encourage hair regrowth and reduce balding areas in patients with androgenic alopecia, without significant absorption or adverse effects.

Too much androgen can cause hair loss; finasteride may help.

This review discusses the influence of androgens on hair and sebaceous growth, emphasizing that response may depend more on peripheral sensitivity than on hormone levels; it reports no new empirical results.